117 results about "Nervous disease" patented technology

The invention discloses a nerve disease detection and analysis method and system, and the method comprises the steps: obtaining a bracelet collection signal, a sphygmomanometer collection signal, a movement behavior image and behavior test data, and extracting tremor intensity features, gait symmetry features and autonomic nerve rhythm features through multi-band decomposition of the bracelet collection signal; analyzing the motion behavior image and the standardized motion test to obtain a motion function score; carrying out heart rate variability analysis to identify a neural function abnormality mode; constructing a neural function state map and calculating a feature weight; predicting a disease progress trend in combination with historical monitoring data; and dynamically adjusting a prediction result through subsequent feedback correction information. Through a mode of combining short-time intensive monitoring and long-term intermittent acquisition, long-term trend prediction and dynamic correction based on initial data are realized, and the reliability and practicability of nerve disease risk assessment in a home scene are remarkably improved.

The invention discloses a neurodegenerative disease diagnosis method for constructing a dynamic brain network based on adaptive graph structure learning, and belongs to the technical field of artificial intelligence. The invention provides a self-adaptive graph structure learning multi-level nerve disease diagnosis framework, which can automatically learn and discover complex and deep connection modes among a plurality of brain areas so as to construct a dynamic brain network. According to the method, a global structure of a brain network is embedded into brain network construction based on a time window through a window mapping module, so that richness and accuracy of brain network topology feature representation are improved; in the fusion process of window features, a learnable time graph convolution module is provided to automatically capture time connectivity across time windows and effectively integrate high-order dynamic topological features extracted from different time windows. And finally, disease diagnosis and classification are realized by using a multi-layer perceptron. According to the method, the identification and classification accuracy of the neurodegenerative diseases under the fMRI data can be effectively improved.

Disclosed herein are compounds, compositions, and methods for promoting neuronal growth and / or improving neuronal structure with the compounds and compositions disclosed herein. Also described are methods of treating diseases or disorders that are mediated by the loss of synaptic connectivity and / or plasticity, such as neurological diseases and disorders, with non-hallucinogenic psychoplastogens.

According to the neural regulation target positioning method and system based on magnetic resonance and electroencephalogram fusion and the focus brain tissue head model construction method based on deep learning, the individual brain structure can be accurately simulated, and a reliable basis is provided for subsequent analysis; according to the electroencephalogram source imaging method based on deep learning, a brain source can be effectively positioned from complex electroencephalogram signals; a target network accurate positioning method based on source imaging further locks and regulates a target spot and a target brain network. The combination of the three can give full play to the advantages of multi-modal data, achieves more accurate and efficient target spot and target network positioning by means of the powerful ability of deep learning, and provides powerful support for nerve disease diagnosis and treatment.

The invention discloses a pharmaceutical composition which comprises anisodine or salt thereof and 2-borneol or related substances thereof. The pharmaceutical composition provided by the invention has a synergistic effect in treatment of cardia-cerebrovascular diseases, especially central nervous diseases such as acute ischemic stroke, can effectively improve the effect of patients with cerebrovascular diseases, especially central diseases such as acute ischemic stroke, and improves the quality of life.

Provided herein are engineered nucleic acids (e.g., expression vectors, including viral vectors, such as lentiviral vectors, adenoviral vectors, AAV vectors, herpes viral vectors, and retroviral vectors) that encode OCT4; KLF4; SOX2; or any combination thereof that are useful, for example, in inducing cellular reprogramming, tissue repair, tissue regeneration, organ regeneration, reversing aging, or any combination thereof in the central nervous system or ex vivo. Also provided herein are recombinant viruses (e.g., lentiviruses, alphaviruses, vaccinia viruses, adenoviruses, herpes viruses, retroviruses, or AAVs) comprising the engineered nucleic acids (e.g., engineered nucleic acids), engineered cells, compositions comprising the engineered nucleic acids, the recombinant viruses, engineered cells, engineered proteins, chemical agents that are capable of activating expression of OCT4; KLF4; SOX2; or any combination thereof, an engineered protein selected from the group consisting of OCT4; KLF4; SOX2; or any combination thereof, an antibody capable of activating expression of OCT4; KLF4; SOX2; or any combination thereof, and methods of treating a disease (e.g., a neurological disease), preventing a disease (e.g., neurological disease), regulating (e.g., inducing or inducing and then stopping) cellular reprogramming, regulating tissue repair, regulating tissue regeneration, or any combination thereof.

The invention discloses a deep brain targeted stimulation method based on a time-frequency interference technology, and relates to the technical field of nerve regulation, and an application system comprises a plurality of pairs of stimulation electrode modules, a data acquisition module, a data preprocessing module, a time-frequency interference stimulation signal generation module, a central control module and a data storage module. According to the method, a multi-azimuth surrounding layout of multiple pairs of stimulation electrodes is combined with a time-frequency interference technology, so that a high-frequency electric field forms constructive interference in a deep brain target area, and meanwhile, a frequency difference is dynamically adjusted based on different organism state requirements; and a closed-loop control system of data acquisition, preprocessing, state evaluation, parameter adjustment and stimulation application is constructed. The problems that a traditional deep brain stimulation technology is low in targeting precision, poor in state guiding efficiency and insufficient in stimulation system stability are solved, the energy focusing degree is improved to 90% or above, the sleep induction time is shortened to 20-30 minutes, and the method can be widely applied to nerve disease treatment and physiological state improvement.

Provided is an apparatus for generating an electroencephalograph (EEG) signal, comprising a processor; and a memory comprising one or more sequences of instructions which, when executed by the processor, causes steps to be performed comprising receiving a first EEG signal and a second EEG signal; extracting a first plurality of features from the first EEG signal and a second plurality of features from the second EEG signal based on a machine learning model; generating a first reconstruction EEG signal and a second reconstruction EEG signal by swapping a same category feature among the first plurality of features and the second plurality of features based on the machine learning model so that the first EEG signal and the second EEG signal match the second reconstruction EEG signal and the first reconstruction EEG signal, respectively.

The invention relates to the technical field of medical image processing, and discloses a method for constructing nerve disease positioning, qualification and evaluation by applying multi-modal magnetic resonance imaging (MRI) image data, which comprises the following steps of: standardizing the multi-modal MRI image data to enable each modal image to have the same spatial resolution; unifying the MRI images of all the modes into a high-order tensor, inputting the high-order tensor into a Tucker decomposition model, outputting a low-dimensional factor matrix and a core tensor, and extracting interaction features between the modes; the extracted interaction features are used for constructing an energy function, a difference term and a regular term are input, the energy function is minimized through a variational method, and an optimized spatial transformation function is output; the feature points are mapped to a unified space through a transformation function, a feature graph structure is constructed, the similarity between nodes is input, optimized graph structure information is output, and image fusion is assisted; by adopting the technical scheme of multi-modal image standardization and tensor decomposition, interaction information between modals is effectively extracted, and the problems of information loss and local feature neglect are solved.

Compositions comprising an isolated population of nanovesicles from a plant, mushroom or algae are provided. Methods of treating muscle and bone diseases, treating neurological diseases, treating age-related disease, inducing muscle differentiation, inducing neuronal differentiation, treating malnutrition, reducing inflammation and reducing oxidative stress by administering a composition comprising an isolated population of nanovesicles from a plant, mushroom or algae are also provided. Methods of delivering a compound to a cell comprising loading the compound into nanovesicles from a plant, mushroom or algae and contacting the cell with the loaded nanovesicles are also provided.

Particles are provided that include a liposome having a negatively charged outer surface and a lipid-drug conjugate, a first layer of cationic polymer such as poly-L-arginine (PLR), that is non-covalently associated with the negatively charged outer surface of the liposome, and a second layer having a mixture of an anionic polymer and polyethylene glycol modified anionic polymer that is non-covalently associated with the first layer. The particles can be formulated as pharmaceutical compositions that are useful in methods that target neurological disorders such as brain tumors and other neurological diseases, and that can deliver and / or transport therapeutic drugs across the blood brain barrier.

The present invention relates to a method for selecting highly potent stem cells for the treatment of neurological disease using TIMP-1, MCP-1, GROα, and IL-6, and a pharmaceutical composition for the prevention or treatment of neurological disease. According to the present invention, a specific combination of markers including TIMP-1, MCP-1, GROα, and IL-6 can be used as a biomarker for selecting stem cells with superior therapeutic (ameliorating) potential in the treatment of neurological disease. Moreover, the application of stem cells exhibiting increased expression or activity of TIMP-1, MCP-1, GROα, and IL-6 factors or the use of substances that regulate (particularly upregulate) these factors in stem cells has a remarkable therapeutic effect on neurological disease due to having high efficacy (potency) and efficiency. Furthermore, the present invention presents the higher therapeutic potential of allogeneic stem cell transplantation.

Provided herein are SOD1 RNAi agents and compositions comprising a SOD1 RNAi agent. Also provided herein are methods of using the SOD1 RNAi agents or compositions comprising a SOD1 RNAi agent in reducing SOD1 expression and / or treating SOD1-mediated neurological disease.

An preventive or therapeutic agent for optic nerve diseases comprises an effective amount of an artificial synapse connector or a nucleic acid encoding the artificial synapse connector.

To provide a preventive or improving agent for neurological disorders caused by nerve damage resulting in reduced nerve function.SOLUTION: The preventive or improving agent contains a combination of quinoa or extract thereof and gluconodeltalactone.SELECTED DRAWING: None

The application of CpG oligonucleotides in drugs for diabetic cardiac autonomic neuropathy: Experiments have confirmed that CpG oligonucleotide 1826 can reduce the activation of satellite glial cells in the stellate ganglion and the expression of inflammatory cytokines, inhibit the expression of purine 2Y12 receptors, and reduce lipid peroxidation damage to alleviate ferroptosis in stellate ganglion neurons, thereby improving cardiac autonomic nerve function. Examples of CpG oligonucleotide 1826 demonstrate that CPG-ODN with anti-inflammatory effects or with anti-damage protective effects on the sympathetic nervous system has preventive and therapeutic effects in diabetic cardiac autonomic neuropathy and sympathetic nerve injury-related diseases.

In some embodiments herein, methods, compositions, and uses for countering the effects of aberrant meningeal lymphatic drainage and / or modulating lymphatic vessels of the central nervous system are described. In some embodiments, methods, compositions, or uses for treating, preventing, or ameliorating symptoms of a neurodegenerative disease associated with aberrant meningeal lymphatic drainage are described. Modulating lymphatic vessels, or countering the effects of aberrant meningeal lymphatic drainage, in accordance with some embodiments, are used to diagnose, treat, prevent, or ameliorate symptoms of neurodegenerative diseases such as Alzheimer's disease (AD) and dementia. Methods of diagnosing and monitoring the progression of neurological diseases are also provided.

The invention relates to the technical field of nerve cell differentiation, and discloses a culture medium for promoting neural differentiation of SH-SY5Y cells. The culture medium disclosed by the invention is prepared from the following components: tazarotene (tazarotene) and a basic culture medium. The culture medium can promote SH-SY5Y cells to present neuron-like differentiation within 5 days, significantly improves the length of neurite and the expression level of neuron markers, and is low in cytotoxicity. The invention provides an efficient, safe and standardized new tool for neural disease in-vitro model construction, drug screening and mechanism research.

Provided herein are ATXN2 RNAi agents and compositions comprising an ATXN2 RNAi agent. Also provided herein are methods of using the ATXN2 RNAi agents or compositions comprising an ATXN2 RNAi agent for reducing ATXN2 expression, and / or treating ATXN2-associated neurological disease in a subject.

kinase inhibitor. 20 26 20 54 07 08 J ul 2 02 6 A B S T R A C T 2 0 2 6 2 0 5 4 0 7 0 8 J u l 2 0 2 6 k i n a s e i n h i b i t o r .

Artificial Intelligence powered Neurological Disease Prediction Device using Wearable Healthcare Data

This disclosure relates to reagents such as antisense oligonucleotides that bind to nucleic acids encoding cryptic exons, thereby inhibiting or preventing ELAVL3 cryptic splicing, and to their use in the treatment or prevention of TDP-43-related neurodegenerative or neurological diseases or conditions associated therewith. In some embodiments, the antisense oligonucleotide is a nucleobase polymer capable of reducing the level or expression of intracellular ELAVL3 cryptic exon RNA and increasing or restoring the expression of functional ELAVL3 protein without substantially incorporating the cryptic exon RNA peptide sequence.

The invention belongs to the technical field of biological medicines, and relates to phenyl naphthalene derivatives and application thereof in preparation of medicines for preventing and treating tumors or medicines for neuroprotection. The compound is a compound shown in a formula I or a formula II or a pharmaceutically acceptable salt thereof. In the formula I, A is not present or is carbonyl, A'is carbonyl, sulfuryl, oximido and imino, R1 is amino, nitryl, acylamino, sulfonamide, aryl methoxy, aryl ethyoxyl, fluorine atom, trifluoromethyl, ureido, amidoxime, amidino and N-methyl sulfonamide, and R2 is hydrogen atom, methoxy, amino, nitryl, acylamino, amidoxime, amidino or fluorine atom; r2 and H2N-A'are located at the adjacent position of a benzene ring, R2 or H2N-A 'is located at the para-position of phenyl, and X1 and X2 are independently selected from CH or N. The phenyl naphthalene derivative provided by the invention has relatively high NQO2 inhibitory activity, and can be used as a chemical drug for tumor treatment and a neuroprotective agent for neurological diseases.

Systems and methods are described for treatment of neurological conditions in which transcranial illumination using infrared and / or near-infrared wavelengths of light are delivered into the brain of a patient using a portable head wearable device. Systems and methods are also described to deliver light to patient tissues for photobiomodulation therapy to treat different neurological conditions with different illumination protocols.

The present invention relates to SYF2 antisense oligonucleotides (ASOs), pharmaceutical compositions containing them, and methods for treating, inhibiting, suppressing, and preventing neurological diseases with them.

Disclosed in the present invention is a pharmaceutical composition, comprising anisodine or a salt thereof and 2-borneol or a related substance thereof. The pharmaceutical composition provided in the present invention exhibits synergistic effects in the treatment of cardiovascular and cerebrovascular diseases, particularly central nervous system diseases such as acute ischemic stroke, and can effectively improve outcomes of patients with cerebrovascular diseases, particularly central nervous system diseases such as acute ischemic stroke, thereby enhancing the quality of life of the patients.

The present invention provides methods and compositions for treating or preventing neurological injury or neurological disorders in a subject in need thereof by administration of an agent that inhibits the activity of TRPM2, e.g., by inhibiting the interaction between TRPM2 and its binding protein, NMDAR. The present invention also provides a peptide-based therapeutic agent, TAT-EE3, and its use in treating or preventing neurological injury or neurological disorders.

Aspects of this invention are related to the use of N-desmethyl ruboxistaurin and pharmaceutically acceptable formulations thereof to modulate GSK3|3 signaling. Some aspects of the invention relate to the use of N-desmethyl ruboxistaurin to inhibit protein kinase C. Some aspects of the invention provide methods of using N-desmethyl ruboxistaurin in the treatment of subjects having a neurological disease and / or psychiatric disorder, including Alzheimer's disease, frontotemporal dementia, behavioral complications of dementia, bipolar disorder, depression, schizophrenia, Parkinson's disease, or neuroinflammation. Some aspects of this invention provide methods of using N-desmethyl ruboxistaurin in treating conditions associated with diabetes mellitus or its complications, or ischemia, inflammation, pulmonary hypertension, congestive heart failure, cardiovascular disease, dermatological disease, or cancer. Some aspects of the invention relate to the use of N-desmethyl ruboxistaurin as an alternative to ruboxistaurin, with a better pharmacokinetic profile, lower potential for prolongation of the electrocardiogram QT interval, and / or a lower potential for adverse drug interactions. In some embodiments, N-desmethyl ruboxistaurin is administered in combination with lithium or other treatments for bipolar disorder.

The invention discloses an application of lignan B in preparation of a medicine for preventing and / or treating neurodegenerative diseases or neurological diseases. In-vitro cell experiments and animal model researches find that the Licarin B can significantly reduce the expression level of ABAD or inhibit the enzymatic activity of ABAD, so that the nerve cell activity is improved, neuroinflammation is reduced, the epileptic seizure frequency is reduced, and the cognitive function is improved. The invention provides the new application of the Licarin B in preparing the medicine for preventing or treating the neurodegenerative diseases and the epilepsy for the first time, and a new way and means are developed for preventing and treating the neurodegenerative diseases and the epilepsy.

The application provides a kind of nanorobot and its control method, carry the modified reverse sodium-potassium pump, can long time, continuously use the ion concentration change of organism itself to realize the regulation of nerve activity, can be widely applied to the intervention of a variety of nervous system excitation / inhibition imbalance related neurological diseases;Through the recognition of specific neuron's axon hillock initial segment by the potential receptor and field driving element, more accurate targeted regulation can be achieved;Through the characteristics of precise control of movement of ultrasonic wave of ultrasonic wave driving element, combined with imaging equipment, brain region targeted movement of nanorobot is realized, the nanorobot and its control method provided by the application improve the existing nanorobot, through the modified functional element, to realize the target brain region targeted guidance, neuron recognition and long-term regulation.